Sanofi SA is expanding its Insulin Valyou Savings Program and will allow uninsured patients in the United States to purchase up to 10 boxes of insulin pens or vials with a valid prescription for $99 per month, beginning in June.
The price of other manufacturers’ leading insulin products is $178 to $300 per vial and $235 to $563 per pack of pens, according to Sanofi.
The move is an expansion of Sanofi’s “Insulin Valyou Savings Program” launched last year and represents a significant savings for patients already enrolled who had been paying $99 for each vial of insulin and $149 for each pack of insulin pens.
Sanofi is not the first company to cut insulin prices in response to intensifying criticism from patients and politicians. Last month, Eli Lilly announced plans to sell a half price, authorized generic version of its popular Humalog insulin injection. The list price for Lilly’s authorized generic, to be sold only in the United States, will be $137.35 per vial.
In terms of profitability, Sanofi said it believes the pricing program is sustainable for the long term. The company’s diabetes business brought in about 2.2 billion euros ($2.5 billion) in U.S. sales last year.
Since Sanofi launched its “Insulins Valyou Savings Program” last April around 12,000 patients have utilized the program, saving about $10 million, the company said.